TLDRs; Palo Alto Networks’ $25B CyberArk deal faced major setbacks before final approval. Talks nearly collapsed in July amid pricing disputes and board disagreements. CyberArk demanded stronger terms, including a $2B reverse termination fee. PANW stock fell 1.01% Friday as investors reacted to new deal disclosures. Palo Alto Networks, Inc. (NASDAQ: PANW) shares fell 1.01% [...] The post Palo Alto Networks, Inc. ($PANW) Stock: Declines Following Turbulent $25B CyberArk Acquisition Talks appeared first on CoinCentral.TLDRs; Palo Alto Networks’ $25B CyberArk deal faced major setbacks before final approval. Talks nearly collapsed in July amid pricing disputes and board disagreements. CyberArk demanded stronger terms, including a $2B reverse termination fee. PANW stock fell 1.01% Friday as investors reacted to new deal disclosures. Palo Alto Networks, Inc. (NASDAQ: PANW) shares fell 1.01% [...] The post Palo Alto Networks, Inc. ($PANW) Stock: Declines Following Turbulent $25B CyberArk Acquisition Talks appeared first on CoinCentral.

Palo Alto Networks, Inc. ($PANW) Stock: Declines Following Turbulent $25B CyberArk Acquisition Talks

2025/10/04 17:21
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDRs;

  • Palo Alto Networks’ $25B CyberArk deal faced major setbacks before final approval.
  • Talks nearly collapsed in July amid pricing disputes and board disagreements.
  • CyberArk demanded stronger terms, including a $2B reverse termination fee.
  • PANW stock fell 1.01% Friday as investors reacted to new deal disclosures.

Palo Alto Networks, Inc. (NASDAQ: PANW) shares fell 1.01% on Friday, closing at $207.19, down $2.11 from the previous session.

After hours, the stock edged slightly higher to $207.50, up 0.15% as trading stabilized. The modest decline followed revelations about the chaotic final stages of Palo Alto’s $25 billion acquisition of CyberArk Software Ltd., one of the largest cybersecurity mergers in history.

Investors appeared to react cautiously as new filings detailed the near-collapse of the deal in July. Despite the eventual success of the acquisition, the tense negotiations raised questions about the transaction’s stability and the valuation pressures facing cybersecurity giants in a consolidating market.

Palo Alto Networks, Inc. (PANW)

 

Deal Began with Rejection, Ended in Tension

The story of Palo Alto’s pursuit of CyberArk began in May 2023, when CEO Nikesh Arora first approached CyberArk’s founder and chairman, Udi Mokady, with an acquisition offer. At the time, Mokady flatly declined, insisting CyberArk would remain independent.

Two years later, in June 2025, the conversation resumed under different circumstances. Arora and Mokady met privately on June 17, and by the end of that month, both firms had signed a nondisclosure agreement to reopen talks. Palo Alto submitted its first non-binding all-stock bid on July 1, valuing CyberArk at $457.99 per share.

Negotiations on the Brink of Collapse

CyberArk countered on July 6 with a sharp demand of $525 per share and a $2 billion reverse termination fee, payable if regulators blocked the deal. Arora balked, calling the terms “excessive,” and returned with $480 per share and no termination fee.

For days, both companies volleyed counteroffers. CyberArk’s board insisted on stronger protection but Palo Alto refused to raise its bid further. The standoff nearly killed the deal on July 10, until Arora agreed to double his termination fee offer to $1 billion, a concession that revived the negotiations.

By mid-July, the two firms signed an exclusivity agreement, locking them into exclusive discussions. But turbulence returned after a Calcalist report claimed Palo Alto might be eyeing another cybersecurity target. Fearing competitors could intervene, Arora accelerated the timeline to finalize the merger.

Final Push to Save the Deal

On July 27, Arora informed Mokady that Palo Alto’s board had withdrawn support for the $495 per-share agreement due to stock price fluctuations, instead proposing $475.21.

The announcement nearly derailed discussions yet again. However, after multiple back-channel talks and internal reassessments, both boards finally approved a revised $25 billion all-stock deal on July 30, 2025.

CyberArk later stated the final offer “provided the best combination of value and shareholder protection.”

Investor Sentiment and Industry Impact

Despite the headline value, the deal’s rollercoaster negotiations appeared to weigh on investor confidence. Analysts noted that Palo Alto’s short-term stock dip reflects market uncertainty about integration costs and the company’s long-term M&A strategy.

Still, the acquisition cements Palo Alto’s dominance in enterprise cybersecurity, expanding its portfolio into privileged access and identity management , key growth sectors as AI-driven cyber threats evolve.

As integration begins, investors will be watching closely to see whether Palo Alto’s $25 billion gamble delivers on its promise or becomes a cautionary tale of ambition meeting market volatility.

The post Palo Alto Networks, Inc. ($PANW) Stock: Declines Following Turbulent $25B CyberArk Acquisition Talks appeared first on CoinCentral.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.06064
$0.06064$0.06064
+1.04%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09